EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Assessing pricing and affordability of HBV treatment in Asia–Pacific region: a barrier to elimination

Jing Chen, Jidong Jia, Hui Zhuang, Wenhong Zhang, Jin Mo Yang, Tawesak Tanwandee, Diana Payawal, Saeed Hamid, Shiv Kumar Sarin, Masao Omata, Guiqiang Wang, George Lau und 1 weitere

Hepatology International · 2025

DOI: 10.1007/s12072-024-10744-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hepatology International, 2025. Verfasst von Jing Chen und 12 weiteren Autor:innen. Beteiligte Einrichtung: JC School of Public Health and Primary Care, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong SAR, China. jingchen001@cuhk.edu.hk. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis B, Chronic, Drug Costs. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The Asia–Pacific (AP) region carries a substantial burden of HBV. Affordable HBV treatment is crucial to attain WHO’s elimination goal. This study assesses the pricing and affordability of HBV treatment in AP.

Methods

A survey conducted among APASL members from 2 Aug to 30 Oct, 2023, gathered data on antiviral HBV drugs, treatment costs covering stages of chronic hepatitis B (CHB), compensated cirrhosis (CC), hepatocellular carcinoma (HCC), liver transplant, and monitoring expenses. Drug costs for TDF and ETV were compared to international reference price (TDF: $30, ETV: $36 per person per year), generating a median price ratio (MPR) where MPR < 1 indicated an acceptable local price. Affordability was evaluated by comparing yearly CHB treatment cost to yearly minimum wage in each country/area, all converted to 2023 US$.

Results

ETV costs ranged from $42 per person per year in Pakistan to $2640 in Malaysia, while TDF costs varied from $12 in mainland China to $2446 in Hong Kong. Almost all MPR exceeded 1. Affordability of HBV treatment varied, with CHB patients in Australia paying 1.4% of minimum yearly wage to get 1 year CHB treatment, in contrast to Myanmar’s 78.6%. Affordability disparities were also evident for patients with CC, HCC, and liver-transplant needs, though monitoring costs were generally affordable.

Conclusions

Despite patent expiration and availability of low-cost generics for TDF and ETV, HBV medication costs in Asia–Pacific region remain high. CHB treatment is generally unaffordable for patients, posing a significant barrier to HBV elimination in this endemic region.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsHepatitis B, ChronicDrug CostsHumansCarcinoma, HepatocellularLiver NeoplasmsAsiaLiver CirrhosisAustraliaTenofovirLiver TransplantationCosts and Cost Analysis

Stichwörter der Autor:innen

AffordabilityAsia–Pacific regionHealth disparitiesHepatitis B virus (HBV)Price

Substanzen

Antiviral AgentsTenofovir

Autor:innen und Institutionen

  • JC School of Public Health and Primary Care, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong SAR, China. jingchen001@cuhk.edu.hk.
  • Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
  • Department of Microbiology and Centre for Infectious Diseases, Peking University Health Science Centre, Beijing, China.
  • Department of Infectious Diseases, National Medical Center for Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Huashan Hospital, Fudan University, Shanghai, 200040,…
  • Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, 06591, Korea.
  • Division of Gastroenterology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Zitieren

APA

Chen, J., Jia, J., Zhuang, H., Zhang, W., Yang, J. M., Tanwandee, T., Payawal, D., Hamid, S., Sarin, S. K., Omata, M., Wang, G., Lau, G., & Apasl Viral Elimination Task Force (2025). Assessing pricing and affordability of HBV treatment in Asia–Pacific region: a barrier to elimination. Hepatology International. https://doi.org/10.1007/s12072-024-10744-9

Vancouver

Chen J, Jia J, Zhuang H, Zhang W, Yang JM, Tanwandee T, et al. Assessing pricing and affordability of HBV treatment in Asia–Pacific region: a barrier to elimination. Hepatology International. 2025. doi:10.1007/s12072-024-10744-9

BibTeX
@article{Chen2025,
  author = {Chen, Jing and Jia, Jidong and Zhuang, Hui and Zhang, Wenhong and Yang, Jin Mo and Tanwandee, Tawesak and Payawal, Diana and Hamid, Saeed and Sarin, Shiv Kumar and Omata, Masao and Wang, Guiqiang and Lau, George and Apasl Viral Elimination Task Force, Apasl Viral Elimination Task Force},
  title = {Assessing pricing and affordability of HBV treatment in Asia–Pacific region: a barrier to elimination},
  journal = {Hepatology International},
  year = {2025},
  doi = {10.1007/s12072-024-10744-9}
}
Kostenlos starten →